Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis

被引:12
作者
Cariani, E. [1 ]
Roli, L. [1 ]
Missale, G. [2 ]
Villa, E. [3 ]
Ferrari, C. [2 ]
Trenti, T. [1 ]
机构
[1] Osped S Agostino Estense, Dept Lab Med, Clin Pathol Toxicol, I-41100 Modena, Italy
[2] Azienda Osped Univ, UO Infect Dis & Hepatol, Parma, Italy
[3] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
关键词
INTERFERON PLUS RIBAVIRIN; SINGLE-NUCLEOTIDE POLYMORPHISM; HCV GENOTYPE 2; PEGYLATED-INTERFERON; IL28B POLYMORPHISMS; GENETIC-VARIATION; VIRAL KINETICS; ANTIVIRAL THERAPY; COST-EFFECTIVENESS; TREATMENT FAILURE;
D O I
10.1038/tpj.2015.28
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Polymorphism of interleukin 28B gene represents a powerful outcome predictor for interferon-based regimens in hepatitis C virus infection. However, some studies report conflicting results. The predictive value of interleukin 28B genotype over the outcome interferon-alpha/ribavirin treatment was thoroughly evaluated and compared with virological predictors of response. Literature revision was performed on PubMed. Pooled odds ratios (ORs) were calculated by fixed-or random-effects models. Heterogeneity and publication bias were also assessed. Sixty-two eligible papers including 20 290 patients were retrieved. Both polymorphisms (rs12979860 and rs8099917) were strongly associated with response (OR = 4.09 and 4.00, respectively), however, the association was weaker for subjects infected with viral genotypes 2 and 3 (OR = 1.52 and 1.49, respectively). Compared with interleukin 28B genotype, the association with response was lower for baseline viremia (OR = 2.15) and higher for rapid virological response (OR = 13.86). These results provide a critical evaluation of interleukin 28B genotype as a pharmacogenetic predictor in hepatitis C patients.
引用
收藏
页码:18 / 29
页数:12
相关论文
共 87 条
[1]   Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy [J].
Akuta, Norio ;
Suzuki, Fumitaka ;
Hirakawa, Miharu ;
Kawamura, Yusuke ;
Sezaki, Hitomi ;
Suzuki, Yoshiyuki ;
Hosaka, Tetsuya ;
Kobayashi, Masahiro ;
Kobayashi, Mariko ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Chayama, Kazuaki ;
Nakamura, Yusuke ;
Kumada, Hiromitsu .
INTERVIROLOGY, 2012, 55 (03) :231-241
[2]   Hepatitis C: The End of the Beginning and Possibly the Beginning of the End [J].
Alter, Harvey J. ;
Liang, T. Jake .
ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) :317-U111
[3]   IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C [J].
Asselah, Tarik ;
De Muynck, Simon ;
Broet, Philippe ;
Masliah-Planchon, Julien ;
Blanluet, Maud ;
Bieche, Ivan ;
Lapalus, Martine ;
Martinot-Peignoux, Michelle ;
Lada, Olivier ;
Estrabaud, Emilie ;
Zhang, Qian ;
El Ray, Ahmed ;
Vidaud, Dominique ;
Ripault, Marie-Pierre ;
Boyer, Nathalie ;
Bedossa, Pierre ;
Valla, Dominique ;
Vidaud, Michel ;
Marcellin, Patrick .
JOURNAL OF HEPATOLOGY, 2012, 56 (03) :527-532
[4]   Complementary Role of Vitamin D Deficiency and the Interleukin-28B rs12979860 C/T Polymorphism in Predicting Antiviral Response in Chronic Hepatitis C [J].
Bitetto, Davide ;
Fattovich, Giovanna ;
Fabris, Carlo ;
Ceriani, Elisa ;
Falleti, Edmondo ;
Fornasiere, Ezio ;
Pasino, Michela ;
Ieluzzi, Donatella ;
Cussigh, Annarosa ;
Cmet, Sara ;
Pirisi, Mario ;
Toniutto, Pierluigi .
HEPATOLOGY, 2011, 53 (04) :1118-1126
[5]   The burden of liver disease in Europe: A review of available epidemiological data [J].
Blachier, Martin ;
Leleu, Henri ;
Peck-Radosavljevic, Markus ;
Valla, Dominique-Charles ;
Roudot-Thoraval, Francoise .
JOURNAL OF HEPATOLOGY, 2013, 58 (03) :593-608
[6]   'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy [J].
Bucci, Cristina ;
von Delft, Annette ;
Christian, Annabel ;
Flemming, Vicki M. ;
Harrison, Abby ;
Halliday, John ;
Collier, Jane ;
Manganis, Chris ;
Klenerman, Paul ;
Irving, William ;
Barnes, Eleanor .
JOURNAL OF GENERAL VIROLOGY, 2013, 94 :1259-1265
[7]   Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C [J].
Camma, Calogero ;
Petta, Salvatore ;
Enea, Marco ;
Bruno, Raffaele ;
Bronte, Fabrizio ;
Capursi, Vincenza ;
Cicchetti, Americo ;
Colombo, Giorgio L. ;
Di Marco, Vito ;
Gasbarrini, Antonio ;
Craxi, Antonio .
HEPATOLOGY, 2012, 56 (03) :850-860
[8]   Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection [J].
Cariani, Elisabetta ;
Villa, Erica ;
Rota, Cristina ;
Critelli, Rosina ;
Trenti, Tommaso .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (08) :1247-1256
[9]   IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population [J].
Cavalcante, Lourianne N. ;
Abe-Sandes, Kiyoko ;
Angelo, Ana Luisa D. ;
Machado, Taisa M. B. ;
Lemaire, Denise C. ;
Mendes, Carlos M. C. ;
Pinho, Joao R. ;
Malta, Fernanda ;
Lyra, Luiz G. C. ;
Lyra, Andre C. .
LIVER INTERNATIONAL, 2012, 32 (03) :476-486
[10]   IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection [J].
Chen, J-Y ;
Lin, C-Y ;
Wang, C-M ;
Lin, Y-T ;
Kuo, S-N ;
Shiu, C-F ;
Chang, S-W ;
Wu, J. ;
Sheen, I-S .
GENES AND IMMUNITY, 2011, 12 (04) :300-309